In an interview for Melanoma Awareness Month, Andrew Pecora, MD, discussed melanoma prevention and treatment for fellow ...

But Lynparza is only approved as a maintenance therapy in Europe, in patients with BRCA1 and BRCA2 mutations with recurrent disease, when the tumour is diminishing in size or has disappeared after ...

Researchers conducted a retrospective multicenter cohort study analyzing 575 female patients with BRCA1 or BRCA2 pathogenic ...

TUESDAY, May 13, 2025 (HealthDay News) — For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial, resulting ...

Discover how genetics is transforming healthcare through personalized medicine, offering tailored treatments, and better outcomes.